No Data
No Data
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $80
Structure Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Structure Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Buy Rating for Structure Therapeutics: Aleniglipron's Competitive Edge in the Oral GLP-1 Market
Structure Therapeutics Analyst Ratings
SA Asks: What's the Best Weight-loss Drug Stock Right Now?